Cancer Res Treat.  2012 Jun;44(2):74-84.

Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer

Affiliations
  • 1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. hak.choy@utsouthwestern.edu
  • 2Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea.

Abstract

Locally advanced non-small cell lung cancer (NSCLC) is a heterogeneous disease, and we have embarked on an era where patients will benefit from individualized therapeutic strategies based on identifiable molecular characteristics of the tumor. The landmark studies demonstrating the importance of molecular characterization of tumors for NSCLC patients, the promising molecular pathways, and the potential molecular targets/agents for treatment of this disease will be reviewed. Understanding these issues will aid in the development of rationally designed clinical trials, so as to determine best means of appropriately incorporating these molecular strategies, to the current standard of radiation and chemotherapy regimens, for the treatment of locally advanced NSCLC.

Keyword

Lung neoplasms; Individualized medicine; Tyrosine kinase inhibitor; Epidermal growth factor receptor; Combined modality therapy

MeSH Terms

Carcinoma, Non-Small-Cell Lung
Combined Modality Therapy
Humans
Precision Medicine
Lung Neoplasms
Receptor, Epidermal Growth Factor
Receptor, Epidermal Growth Factor
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr